Patents by Inventor Oleksandr Prokopovyeh Kozynchenko

Oleksandr Prokopovyeh Kozynchenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9278170
    Abstract: Whole blood is treated extracorporeally to remove substances contrary to health using mesoporous/microporous or macroporopus/microporous carbon in the form of beads or a channel monolith. The carbon may be the result of carbonizing a mesoporous or macroporous phenolic resin. Substances contrary to health include externally introduced toxins such as bacterially derived staphylococcus enterotoxins A, B, TSST-1 or autologous, biologically active molecules with harmful, systemic effects when their activity is excessive or unregulated. Examples include the removal of inappropriate amounts of pro- or anti-inflammatory molecules and toxic mediators of systemic inflammatory response syndrome related to sepsis, cardio-pulmonary by-pass surgery, ischaemic reperfusion injury; the removal of larger molecular weight and protein bound uremic toxins related to kidney and hepatic toxins related to liver failure and the removal of toxins relevant to biological and chemical warfare.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: March 8, 2016
    Assignee: IMMUNTRIX THERAPEUTICS, INC.
    Inventors: Stephen Robert Tennison, Oleksandr Prokopovyeh Kozynchenko, Anthony Paul Rawlinson, Gary James Phillips, Carol Angela Howell, Susan Rachel Sandeman, Sergey Victorovich Mikhalovsky
  • Publication number: 20130072845
    Abstract: Whole blood is treated extracorporeally to remove substances contrary to health using mesoporous/microporous or macroporopus/microporous carbon in the form of beads or a channel monolith. The carbon may be the result of carbonising a mesoporous or macroporous phenolic resin. Substances contrary to health include externally introduced toxins such as bacterially derived staphylococcus enterotoxins A, B, TSST-1 or autologous, biologically active molecules with harmful, systemic effects when their activity is excessive or unregulated. Examples include the removal of inappropriate amounts of pro- or anti-inflammatory molecules and toxic mediators of systemic inflammatory response syndrome related to sepsis, cardio-pulmonary by-pass surgery, ischaemic reperfusioninjury; the removal of larger molecular weight and protein bound uremic toxins related to kidney and hepatic toxins related to liver failure and the removal of toxins relevant to biological and chemical warfare.
    Type: Application
    Filed: December 9, 2010
    Publication date: March 21, 2013
    Applicants: University of Brighton, MAST Carbon International Ltd
    Inventors: Stephen Robert Tennison, Oleksandr Prokopovyeh Kozynchenko, Anthony Paul Rawlinson, Gary James Phillips, Carol Angela Howell, Susan Rachel Sandeman, Sergey Victorovich Mikhalovsky